/hantavirus-tenerife.tmb-768v.png?sfvrsn=ed339623_1 "21 Nations Launch Joint Andes Virus Research Effort")
21 Nations Launch Joint Andes Virus Research Effort
A globally coordinated research initiative, known as NAVIS, has launched across 21 countries to study the Andes virus (ANDV) following an outbreak linked to the MV Hondius cruise ship. This natural history study aims to gather data on transmission dynamics, incubation periods, and immune responses by tracking exposed individuals, according to participating research institutions and global health authorities.
What is the NAVIS initiative?
NAVIS is a prospective, harmonized research study designed to generate comparable datasets during health emergencies. According to the UK Health Security Agency (UKHSA), the protocol for the study was developed by Hospital Germans Trias i Pujol in Spain. It was deployed following an emergency consultation by the Hantavirus Collaborative Open Research Consortium (CORC), which mobilized over 1,600 experts from more than 130 countries.
The study utilizes the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) framework. This platform enables standardized data and sample collection, which researchers intend to use to inform the development of medical countermeasures, including vaccines, tests, and treatments.
Did You Know?
The NAVIS study protocol was developed for immediate deployment by Hospital Germans Trias i Pujol in Badalona, Spain, as part of a rapid response to the ANDV outbreak.
Why does this research matter?
The Andes virus presents a limited window for scientific investigation, making rapid, coordinated action essential to avoid losing critical data, according to the World Health Organization (WHO). Sylvie Briand, Chief Scientist at the WHO, stated that future outbreak responses should focus on activating existing research systems rather than building them during a crisis.
The initiative is supported by ANRS Emerging Infectious Diseases (ANRS-MIE) under the EU-funded BE READY project. By establishing these networks before emergencies occur, researchers hope to accelerate the creation of medical countermeasures. Yazdan Yazdanpanah of ANRS-MIE noted that the rapid launch of NAVIS across 21 countries demonstrates the utility of pre-established research networks.
Expert Insight:
The transition toward pre-planned, geographically distributed research infrastructure marks a significant shift in how the global health community manages emerging pathogens. By embedding research capacity within national ethics committees and surveillance platforms, institutions like Emory University and the National Centre for Infectious Diseases can act as localized hubs for global data collection, potentially reducing the time required to understand viral kinetics in future outbreaks.
What may happen next?
As the NAVIS study progresses, researchers are likely to generate longitudinal data that could refine current understanding of how ANDV causes severe disease. Analysts expect that the standardized protocols could serve as a model for future pathogen family research, as outlined in the WHO’s R&D Blueprint. If successful, this approach could allow health authorities to deploy similar rapid-response research frameworks more efficiently during future epidemics.
Frequently Asked Questions
What is the purpose of the NAVIS study?
NAVIS is a natural history study designed to improve understanding of ANDV transmission dynamics, incubation periods, immune responses, viral kinetics, and determinants of severe disease.
Which countries are involved in this initiative?
Participating countries include Australia, Belgium, Canada, the Democratic Republic of the Congo, Denmark, France, Germany, Greece, Ireland, Italy, Japan, the Netherlands, New Zealand, Singapore, South Africa, Spain, Switzerland, Türkiye, the United Kingdom, and the United States.
How does this research support future outbreak responses?
By using standardized approaches and pre-established research networks, the initiative aims to generate comparable datasets that can accelerate the development of medical countermeasures like vaccines and treatments, rather than building research systems during a crisis.
How do you believe global collaboration changes the speed of medical innovation during a health crisis?